Related Experiment Videos
Oxaliplatin-based combined-modality therapy for rectal cancer.
1Department of Radiation Oncolgy, Memorial SLoan-Kettering Cancer Center, New York, NY 10021, USA.
Seminars in Oncology
|October 3, 2003
Summary
This review examines conventional and novel oxaliplatin-based treatments for resectable rectal cancer, comparing preoperative and postoperative combined-modality therapies alongside surgery.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Cancer
Background:
- Rectal cancer treatment involves surgery and combined-modality therapy.
- Conventional approaches include postoperative or preoperative therapy based on tumor stage.
Purpose of the Study:
- To review current treatment strategies for resectable rectal cancer.
- To present results of novel oxaliplatin-based combined-modality therapies.
Main Methods:
- Review of existing treatment protocols for rectal cancer.
- Analysis of outcomes for conventional combined-modality therapies.
- Evaluation of novel oxaliplatin-based regimens.
Main Results:
- Comparison of two standard treatment pathways: surgery followed by adjuvant therapy versus neoadjuvant therapy before surgery.
- Presentation of data on oxaliplatin-based regimens in rectal cancer treatment.
Conclusions:
- Established treatment modalities for rectal cancer include surgery with adjuvant or neoadjuvant combined-modality therapy.
- Emerging oxaliplatin-based strategies offer potential advancements in rectal cancer management.